Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 551 to 575 of 797

TitleReference numberPublishedLast updated
Ustekinumab for treating active psoriatic arthritisTA340
Ustekinumab for the treatment of adults with moderate to severe psoriasisTA180
Everolimus for advanced renal cell carcinoma after previous treatmentTA432
Apremilast for treating active psoriatic arthritisTA433
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutationTA429
Sofosbuvir–velpatasvir for treating chronic hepatitis CTA430
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomibTA427
Everolimus with exemestane for treating advanced breast cancer after endocrine therapyTA421
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA422
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimensTA423
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancerTA424
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemiaTA425
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemiaTA426
Ticagrelor for preventing atherothrombotic events after myocardial infarctionTA420
Dapagliflozin in combination therapy for treating type 2 diabetesTA288
Nivolumab for previously treated advanced renal cell carcinomaTA417
Dapagliflozin in triple therapy for treating type 2 diabetesTA418
Apremilast for treating moderate to severe plaque psoriasisTA419
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitorTA415
Elbasvir–grazoprevir for treating chronic hepatitis CTA413
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanomaTA414
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerTA411
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastasesTA412
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA406
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitorsTA407

Results per page

  1. 10
  2. 25
  3. 50
  4. All